This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Apr;19(4):438-439.

doi: 10.1016/S1470-2045(18)30160-8. Epub 2018 Mar 12.

ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?

Jessica J Lin¹, Justin F Gainor²

Affiliations

Affiliations

¹ Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
² Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Electronic address: jgainor@partners.org.

PMID: 29545096
DOI: 10.1016/S1470-2045(18)30160-8

Comment

ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?

Jessica J Lin et al. Lancet Oncol. 2018 Apr.

. 2018 Apr;19(4):438-439.

doi: 10.1016/S1470-2045(18)30160-8. Epub 2018 Mar 12.

Authors

Jessica J Lin¹, Justin F Gainor²

Affiliations

¹ Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
² Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Electronic address: jgainor@partners.org.

PMID: 29545096
DOI: 10.1016/S1470-2045(18)30160-8

No abstract available

PubMed Disclaimer

Comment on

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators. Garassino MC, et al. Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12. Lancet Oncol. 2018. PMID: 29545095 Free PMC article. Clinical Trial.

Similar articles

Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
Waqar SN, Morgensztern D. Waqar SN, et al. Expert Rev Clin Immunol. 2015;11(8):871-3. doi: 10.1586/1744666X.2015.1054374. Epub 2015 Jun 7. Expert Rev Clin Immunol. 2015. PMID: 26051156 Review.
Lung cancer in 2016: immunotherapy comes of age.
Mitchell PL, John T. Mitchell PL, et al. Lancet Respir Med. 2016 Dec;4(12):947-949. doi: 10.1016/S2213-2600(16)30379-4. Epub 2016 Nov 22. Lancet Respir Med. 2016. PMID: 27890503 No abstract available.
Genomic Features of Response to Combination Immunotherapy in Lung Cancer.
Früh M, Peters S. Früh M, et al. Cancer Cell. 2018 May 14;33(5):791-793. doi: 10.1016/j.ccell.2018.04.005. Cancer Cell. 2018. PMID: 29763618
Immunotherapy for lung cancer: Targeting the PD-1 pathway.
Vafadar S. Vafadar S. JAAPA. 2017 Jun;30(6):48-50. doi: 10.1097/01.JAA.0000515557.14603.c7. JAAPA. 2017. PMID: 28538431
[Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S, Li J. Wang S, et al. Zhongguo Fei Ai Za Zhi. 2016 Oct 20;19(10):682-686. doi: 10.3779/j.issn.1009-3419.2016.10.09. Zhongguo Fei Ai Za Zhi. 2016. PMID: 27760599 Free PMC article. Review. Chinese.

See all similar articles

Cited by

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S, Wang W. Peng S, et al. Mol Cancer. 2019 Nov 20;18(1):165. doi: 10.1186/s12943-019-1073-4. Mol Cancer. 2019. PMID: 31747941 Free PMC article.
Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review.
Wang NH, Lei Z, Yang HN, Tang Z, Yang MQ, Wang Y, Sui JD, Wu YZ. Wang NH, et al. Ann Transl Med. 2022 Dec;10(24):1406. doi: 10.21037/atm-22-6049. Ann Transl Med. 2022. PMID: 36660640 Free PMC article. Review.
Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.
Day TF, Kallakury BVS, Ross JS, Voronel O, Vaidya S, Sheehan CE, Kasid UN. Day TF, et al. Mol Cancer Res. 2019 May;17(5):1207-1219. doi: 10.1158/1541-7786.MCR-18-0731. Epub 2019 Jan 15. Mol Cancer Res. 2019. PMID: 30647104 Free PMC article.
Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies.
Meng Y, Bai R, Cui J. Meng Y, et al. Thorac Cancer. 2023 May;14(13):1121-1134. doi: 10.1111/1759-7714.14858. Epub 2023 Apr 2. Thorac Cancer. 2023. PMID: 37005552 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information